{
    "clinical_study": {
        "@rank": "109129", 
        "brief_summary": {
            "textblock": "In this phase II study, patients with solid tumors will receive treatment with hiltonol and\n      autologous dendritic cells."
        }, 
        "brief_title": "Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of advanced solid tumors\n\n          -  Measurable disease\n\n          -  Performance status 0, 1 or 2.\n\n          -  Adequate renal, hepatic and bone marrow function\n\n          -  Availability of tumor tissue, for maturing dendritic cells\n\n        Exclusion Criteria:\n\n          -  Clinically relevant diseases or infections.\n\n          -  concurrent participation in other clinical trial or administration or other\n             antitumoral treatment\n\n          -  Concurrent cancer, with the exceptions allowed by the PI.\n\n          -  Pregnant or breast feeding women\n\n          -  immunosuppressant treatment\n\n          -  known uncontrolled central nervous system metastasis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734564", 
            "org_study_id": "CD-2010-01"
        }, 
        "intervention": {
            "intervention_name": "Hiltonol and autologous dendritic cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pamplona", 
                    "country": "Spain", 
                    "state": "Navarra", 
                    "zip": "31008"
                }, 
                "name": "Clinica Universidad de Navarra"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors", 
        "overall_official": {
            "affiliation": "Clinica Universidad de Navarra", 
            "last_name": "Jose Luis Perez Gracia, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "8-10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety (Common Toxicity Criteria 4.0)", 
            "safety_issue": "Yes", 
            "time_frame": "8-10 weeks"
        }, 
        "source": "Clinica Universidad de Navarra, Universidad de Navarra", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Clinica Universidad de Navarra, Universidad de Navarra", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}